Malignant Pleural Mesothelioma - A Pipeline Analysis Report

Malignant pleural mesothelioma industry analysis

Malignant pleural mesothelioma is a rare and aggressive cancer that develops in a thin layer of tissue surrounding the lungs known as pleura. MPM is caused by the inhalation of microscopic asbestos fibers. Once the person inhales asbestos dust, the human body struggles to eliminate the needle-like fibers of asbestos from lungs. According to the NIH, the incidences of MPM in Europe is about 20 per million inhabitants, and it is increasing globally. This will subsequently demand the need for the development of innovative treatments for malignant pleural mesothelioma, driving the market’s growth.

Furthermore, according to the CDC, the median survival of MPM patients is approximately one year from the time of diagnosis. Also, the global estimated incidences of MPM is around 2,000-3,000 cases annually, and the number is likely to increase owing to the exposure to asbestos, in turn, will influence the malignant pleural mesothelioma market growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for the treatment of malignant pleural mesothelioma. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Malignant pleural mesothelioma market value: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the drug development for malignant pleural mesothelioma. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• AstraZeneca
• Bayer
• Pfizer
• Selecta Biosciences

Therapeutic assessment of the drug development for malignant pleural mesothelioma by route of administration

• IV
• Oral
• Intrapleural
• Intratumoral
• Subcutaneous
• Intratumoral/subcutaneous

The IV route of administration (ROA) involves the application of the drug directly into a vein.

Therapeutic assessment of the drug development for malignant pleural mesothelioma by therapy

• Monotherapy
• Combination therapy

Malignant pleural mesothelioma industry analysis, all the molecules in the drug development for malignant pleural mesothelioma are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for malignant pleural mesothelioma?
• What are the companies that are currently involved in the drug development of malignant pleural mesothelioma?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.